ARMC7

Across TCGA pan-cancer cohorts, ARMC7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARMC7 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARMC7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARMC7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and OV show a favorable association.

HNSC, LUAD, and OV are the cancer types where ARMC7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.890	1.000	.005	16	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.671	.013	9	view →
OV	DFS	Median	All	0.858	0.599	.045	4	view →
UCEC	OS	Median	All	1.000	0.837	.037	4	view →
PDAC	OS	Median	III,IV	0.478	1.000	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARMC7–HNSC (DFS)

Open the HNSC breakdown →